Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NVR 3-778 + peginterferon alfa-2a
- Development stage
- Discontinued
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Subcutaneous
01
Overview
NVR 3-778 + peginterferon alfa-2a is a combination therapy composed of NVR 3-778, a small-molecule hepatitis B virus (HBV) capsid assembly modulator, and peginterferon alfa-2a, a pegylated recombinant human interferon used as an immunomodulatory and antiviral agent. NVR 3-778 inhibits HBV replication by targeting and modulating the core protein, interfering with viral capsid assembly and blocking pregenomic RNA encapsidation and subsequent production of infectious HBV DNA and RNA particles. Peginterferon alfa-2a activates human type I interferon receptors, leading to JAK/STAT pathway signaling and induction of innate antiviral gene expression. The combination has been explored in clinical contexts for the treatment of chronic hepatitis B, aiming to provide additive or synergistic antiviral effects by targeting different stages of the HBV life cycle[1][2][3][5].
- Other names
- peginterferon alfa-2a
02
Targets
HBc (Hepatitis B virus core protein)IFNAR1 (Interferon alpha/beta receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on NVR 3-778 + peginterferon alfa-2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NVR 3-778 + peginterferon alfa-2a.